PHARMA SOFTWARE SOLUTIONS LIMITEDActive

Company number 05009289Private limited companyIncorporated 2004
⚠ Accounts overdue. The next accounts were due on 25 Oct 2026 and had not been filed when the register was last updated.

Key figures

£11,002+91.6%
Net assets 2024/25
+3.5%
Average annual growth 2020/21–2024/25
05 k10 k15 k2020/212021/222022/232023/242024/25

Like most small UK companies, PHARMA SOFTWARE SOLUTIONS LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
010 k20 k2020/212021/222022/232023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222022/232023/242024/25
Total assets11,38713,06910,28812,31318,054
Total liabilities1,0502,9734,9355,9116,362
Net assets / total equity9,5939,2664,6935,74211,002
Average number of employees22222

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: PHARMA SOFTWARE SOLUTIONS LIMITED

Company

PHARMA SOFTWARE SOLUTIONS LIMITED is a private limited company registered with Companies House under company number 05009289. It was incorporated on 7 Jan 2004. Its status is active. The registered office is in Manchester (M25). Its nature of business (SIC 2007) is other information technology service activities (62090).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Jan 2025); the company files micro-entity accounts. Net assets were £11,002, up 91.6% on the previous year. Total assets were £18,054 and total liabilities £6,362. The company had an average of 2 employees. Figures are available for 5 financial years (2020/21–2024/25).

Control and charges

2 persons with significant control are registered.

Filing deadlines

The next accounts are due by 25 Oct 2026. The next confirmation statement is due by 9 Nov 2026.